Features of patients with AOSD with and without MAS*
| non-MAS (n=174) | MAS (n=35) | P values | |
| Demographic | |||
| Age, mean±SD (years) | 36.9±13.5 | 32±11.4 | 0.028 |
| Gender (F/M) | 138/36 | 28/7 | 0.927 |
| Deaths, n (%) | 6 (3.4) | 6 (17.1) | 0.001 |
| Clinical manifestations | |||
| Arthritis, n (%) | 119 (68.4) | 25 (71.4) | 0.723 |
| Eruption, n (%) | 123 (70.7) | 28 (80) | 0.262 |
| Abnormal liver function, n (%) | 143 (82.2) | 33 (94.3) | 0.073 |
| Decreased blood cells, n (%) | 1 (0.6) | 26 (74.3) | <0.001 |
| Central nervous system involvement, n (%) | 0 (0) | 7 (20) | <0.001 |
| Haemorrhagic manifestations, n (%) | 0 (0) | 6 (17.1) | <0.001 |
| Splenomegaly, n (%) | 36 (20.7) | 8 (22.9) | 0.774 |
| Hepatomegaly, n (%) | 3 (1.7) | 4 (11.4) | 0.016 |
| Enlarged lymph nodes, n (%) | 107 (61.5) | 28 (80) | 0.037 |
| Laboratory features | |||
| White cell count (×109/L) | 14.2 (3.6–50.4) | 6.3 (0.2–37.7) | <0.001 |
| Neutrophil count (×109/L) | 12.1 (1.13–48.13) | 5.2 (0–36.3) | <0.001 |
| Lymphocyte count (×109/L) | 1.28 (0.4–4.71) | 0.7 (0.15–3.08) | <0.001 |
| Haemoglobin (g/L) | 109 (53–141) | 85 (63–134) | <0.001 |
| Platelet count (×109/L) | 295 (34–564) | 81 (8–368) | <0.001 |
| Ferritin (ng/mL) | 1813 (25–42 138) | 2000 (459–217 988) | 0.007 |
| Aspartate aminotransferase (U/L) | 40 (7–555) | 157 (17–2888) | <0.001 |
| Alanine aminotransferase (U/L) | 37 (5–539) | 143 (11–2407) | <0.001 |
| Triglycerides (mmol/L) | 1.2 (0.4–3.8) | 2.56 (0.7–19.3) | <0.001 |
| Fibrinogen (g/L) | 4.3 (0.9–8.1) | 1.49 (0.31–5.59) | <0.001 |
| ESR (mm/hour) | 69 (3–132) | 27 (1–126) | <0.001 |
| CRP (mg/L) | 83.0 (0.27–498.9) | 75.6 (1.5–250) | 0.772 |
| Scores | |||
| HScore, median (range) | 68 (33-156) | 196 (98–333) | <0.001 |
| MS score, median (range) | −1.17 (−1.26 to 2.52) | 1.05 (−1.26 to 26.55) | <0.001 |
*Values are expressed as n (%) or median (range).
AOSD, adult-onset Still’s disease; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; F, female; M, male; MAS, macrophage activation syndrome.